Abstract
Preeclampsia is a major cause of obstetric and perinatal morbidity and mortality ( 1). Guidelines recommend acetylsalicylic acid (ASA) prophylaxis in pregnant women with certain risk factors to mitigate maternal vascular dysfunction and prevent consequences of preeclampsia ( 1–3). According to Society of Obstetricians and Gynaecologists of Canada (SOGC) guidelines, low-dose ASA (75 mg/day to 162 mg/day) should be prescribed for high-risk patients. Risk factors include advanced maternal age, personal or family history of preeclampsia, pre-existing medical conditions, obesity, and multiple pregnancy. Therapy should be initiated before 16 weeks’ gestation and continued until delivery...

This publication has 8 references indexed in Scilit: